GeminIQ Website Logo

Viewing ATXI free

Subscribe for full history, 90+ metrics, screener, watchlist...

AVENUE THERAPEUTICS, INC.

ATXI

Subscribe to unlock 17+ years of data

Financial Statements

Values in Millions ($)
2026-06-30
2026-03-31
2025-12-31
2025-09-30
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only column

Financial statements beyond 3 years are for subscribers only.

Unlock 17+ years of income statements, balance sheets, and cash flow statements

Start 7-day free trial
Subscriber-only column
Cash And Cash Equivalents At Carrying Value
223434335320
Assets Current
Prepaid Expense And Other Assets Current
000000000000
Assets
223444335321
Accounts Payable And Accrued Liabilities Current
-----------1
Liabilities Current
Derivative Liabilities Current
000000000013
Liabilities Current
111111111115
Liabilities
111111111115
Preferred Stock Value
00000000000-
Common Stock Value
000000000000
Stockholders Equity
Stockholders Equity
11223233432-5
Additional Paid In Capital
107107107108108108105104103989388
Retained Earnings Accumulated Deficit
-107-106-105-105-104-104-103-101-98-95-91-92
Minority Interest
--0-1-1-1-1-1-1-1-1-1
Liabilities And Stockholders Equity
223444335321
Preferred Stock Par Or Stated Value Per Share
000000000000
Preferred Stock Shares Authorized
222222222222
Preferred Stock Shares Issued
00000000000-
Preferred Stock Shares Outstanding
00000000000-
Common Stock Par Or Stated Value Per Share
000000000000
Common Stock Shares Authorized
2002002002002002002002002002007575
Common Stock Shares Issued
333333221100
Shares Outstanding
333333221100

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Custom Table

0/5
Search a metric to start building a table

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Interactive Financial Visualizations

0/1
Search a metric to start building a visual

Subscribe to unlock 17+ years of data

Earnings Market Reaction

Fiscal Year
Q1 1 Month
Q1 2 Month
Q1 3 Month
Q2 1 Month
Q2 2 Month
Q2 3 Month
Q3 1 Month
Q3 2 Month
Q3 3 Month
Q4 1 Month
Q4 2 Month
Q4 3 Month
2026-43.40%-47.17%-47.99%---------
20254.00%35.96%84.00%41.35%34.62%38.46%1.17%-9.76%-73.42%127.59%-16.93%12.26%
2024-7.40%-8.36%-28.22%2.63%1.41%-11.11%-2.13%9.57%-27.66%-16.00%-30.41%-0.42%
2023----25.61%-33.30%-64.15%-22.16%-3.90%-28.90%-15.31%-66.67%-71.83%

Earnings Market Reaction data beyond 3 years is for subscribers only.

Unlock the full earnings market reaction history

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics
2026-06-30
2026-03-31
2025-12-31
2025-09-30
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only column

Metric history beyond 3 years is for subscribers only.

Unlock 17+ years of history across 90+ calculated metrics

Start 7-day free trial
Subscriber-only column
Leverage & Debt
Debt to Equity
2.47
1.06
0.60
0.62
0.47
0.54
0.44
0.59
0.30
0.74
1.83
-1.11
Per Share Metrics
Diluted EPS TTM
-
-
-
-
-
-
-
-
-
-
-
-96.47
Free Cash Flow Per Share TTM
-0.42
-0.33
-0.59
-0.55
-1.58
-2.39
-6.97
-6.62
-7.68
-19.57
-66.92
-104.39
Dividend Per Share TTM
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Margin Metrics
Operating Profit Margin TTM
-
-134.76%
-219.59%
-279.77%
-452.99%
-
-
-
-
-
-
-
Net Profit Margin TTM
-
-124.36%
-207.19%
-267.52%
-437.32%
-
-
-
-
-
-
-
Growth Metrics
Net Revenue Growth (1Y)
-100.00%
-
-
-
-
-
-
-
-
-
-
-
Net Income Growth (1Y)
-54.97%
-80.96%
-75.03%
-60.03%
5.70%
28.88%
12.29%
-10.67%
-50.33%
-14.20%
192.15%
108.75%
EPS Growth (1Y)
-56.49%
-82.83%
-89.67%
-79.91%
-62.89%
-75.62%
-87.76%
-93.96%
-95.40%
-88.67%
-39.88%
-62.39%
Valuation Metrics
P/E TTM
-0.33
-0.55
-0.73
-0.67
-0.10
-0.10
-0.22
-0.42
-0.67
-0.87
-0.16
-0.55
P/B TTM
1.62
0.80
1.16
1.09
0.23
0.38
1.40
2.41
1.02
3.28
2.61
-1.27
P/S TTM
-
0.68
1.52
1.78
0.46
-
-
-
-
-
-
-
Market Cap
922.59K
955.18K
2.13M
2.51M
638.94K
891.24K
2.59M
3.98M
3.91M
6.22M
1.71M
5.74M
Enterprise Value
-1.02M
-1.46M
-725.20K
-1.20M
-2.69M
-2.61M
-3.59K
1.39M
-1.01M
3.02M
-77.74K
5.58M
Calculated Values
Free Cash Flow TTM
-1.38M
-1.09M
-1.83M
-1.74M
-5.02M
-7.09M
-9.03M
-10.59M
-8.59M
-11.00M
-9.45M
-11.30M
Net Debt
-1.94M
-2.42M
-2.86M
-3.71M
-3.33M
-3.50M
-2.59M
-2.60M
-4.92M
-3.19M
-1.78M
-161.00K
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of data

Insider Transactions

2024-12-02Sale
Owner: Herskowitz, Neil
Title: -
Shares: 23
Price/Share: $2.00
Value: $46.00
Shares Owned: 97
Relationship: Director
Ownership: Direct
2024-11-05Sale
Owner: Kranzler, Jay D
Title: -
Shares: 61
Price/Share: $2.24
Value: $136.64
Shares Owned: 559
Relationship: Director
Ownership: Direct
2024-09-30Purchase
Owner: Kranzler, Jay D
Title: -
Shares: 497
Price/Share: $2.50
Value: $1,242.50
Shares Owned: 620
Relationship: Director
Ownership: Direct
2023-12-11Sale
Owner: Davidow, Robert L
Title: -
Shares: 264,000
Price/Share: $0.14
Value: $36,960.00
Shares Owned: 681,000
Relationship: TenPercentOwner
Ownership: Direct
2023-09-08Purchase
Owner: Fortress, Biotech, Inc.
Title: -
Shares: 418,410
Price/Share: $0.72
Value: $301,255.20
Shares Owned: 1,032,390
Relationship: TenPercentOwner
Ownership: Direct

Subscribe to unlock 17+ years of data

Institutional Ownership

No data available for chart
2024-12-31
14.87%
Inst. Shares: 192,628
Shares Outstanding: 1,295,207
2024-09-30
12.34%
Inst. Shares: 197,515
Shares Outstanding: 1,600,189
2024-06-30
10.41%
Inst. Shares: 116,349
Shares Outstanding: 1,117,769
2024-03-31
196.54%
Inst. Shares: 1,104,634
Shares Outstanding: 562,031
2023-12-31
211.76%
Inst. Shares: 299,053
Shares Outstanding: 141,222

AVENUE THERAPEUTICS, INC. (ATXI) — SEC Financial Statements & Analysis

AVENUE THERAPEUTICS, INC. (ATXI) is a pharmaceutical preparations company, incorporated in DE. AVENUE THERAPEUTICS, INC. trades on OTC as: ATXI. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), AVENUE THERAPEUTICS, INC. reported a -100.00% year-over-year revenue growth, a Debt-to-Equity ratio of 2.47x, a Price-to-Sales (P/S) ratio of 0.68x (TTM), a Price-to-Book (P/B) ratio of 1.62x (TTM), at a market cap of $922.59K. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y
-100.00%
Debt To Equity
2.47x
P/S TTM
0.68x
P/B TTM
1.62x
Market Cap
$922.59K

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is AVENUE THERAPEUTICS, INC. in?

AVENUE THERAPEUTICS, INC. (ATXI) operates in the Pharmaceutical Preparations industry.

What is ATXI's market cap?

AVENUE THERAPEUTICS, INC. (ATXI) has a market capitalization of $922.59K as of 2026-06-30.

What exchange does ATXI trade on?

AVENUE THERAPEUTICS, INC. (ATXI) trades on the OTC.

Where is AVENUE THERAPEUTICS, INC. incorporated?

AVENUE THERAPEUTICS, INC. is incorporated in DE.

Wall Street's data.
Main Street's price.